Analysen von Richard Vosser
| 11.04.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 04.04.23 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 03.04.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.03.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 25.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.03.23 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 23.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 13.03.23 | Sanofi Overweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 09.03.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.03.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 02.03.23 | Merck Overweight | JP Morgan Chase & Co. | |
| 28.02.23 | Bayer Neutral | JP Morgan Chase & Co. | |
| 09.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 09.02.23 | Bayer Neutral | JP Morgan Chase & Co. | |
| 07.02.23 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 06.02.23 | Bayer Neutral | JP Morgan Chase & Co. | |
| 03.02.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.02.23 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 02.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 01.02.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 31.01.23 | Merck Overweight | JP Morgan Chase & Co. | |
| 27.01.23 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 26.01.23 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 25.01.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 19.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 18.01.23 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 11.01.23 | Bayer Neutral | JP Morgan Chase & Co. | |
| 05.01.23 | MorphoSys Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 03.01.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.01.23 | GSK Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 03.01.23 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 03.01.23 | Merck Overweight | JP Morgan Chase & Co. | |
| 03.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.01.23 | MorphoSys Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Bayer Neutral | JP Morgan Chase & Co. | |
| 14.11.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 11.11.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 10.11.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 09.11.22 | Merck Overweight | JP Morgan Chase & Co. | |
| 09.11.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 08.11.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 03.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 02.11.22 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 31.10.22 | Bayer Overweight | JP Morgan Chase & Co. | |
| 31.10.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 28.10.22 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 27.10.22 | Merck Overweight | JP Morgan Chase & Co. | |